Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Battleground GLP-1s: After Chinese Firms, Glenmark Debuts Liraglutide; More Coming

Executive Summary

After China, India sees the arrival of a biosimilar to Novo Nordisk’s Victoza at a sharp discount, while action also appears to be heating up for the Danish firm's high-flying GLP-1, semaglutide, in both markets.

You may also be interested in...



China’s Regulators Accept Jiuyuan Gene’s Application For Ozempic Biosimilar

Jiuyuan Gene scored a country-wide first as China’s regulator accepted its marketing application for a semaglutide biosimilar in type 2 diabetes that will be marketed as Jiyoutai.

Cipla Points To Large GLP-1 India Opportunity Amid Speculation On Lilly Deal

Cipla refers to the transformational potential of GLP-1s in India, a market with 100m-plus diabetics and rising obesity, amid plans for oral semaglutide and speculation on partnering possibilities. A recalibration in the firm’s specialty products thrust is also seen. 

France Takes Aim At Off-Label Use Of GLP-1s Amid Continuing Shortages

A new expert body is examining the use of semaglutide and other GLP-1 receptor agonists, focusing on safety risks and ongoing supply issues.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153216

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel